NSD2 and plasma cell myeloma: Histone-lysine N-methyltransferase NSD2/MMSET was first implicated in cancer as a target for rearrangement [t(4;14)(p16.3;q32)] in 15%–20% of multiple myeloma (MM) patients (Chesi et al., 1998).